End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
4.08 USD | -0.49% | -2.39% | -6.64% |
25/02 | Birzeit Pharmaceuticals Company Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
09/01 | What does the Gotham City report say about Grifols? | RE |
Business Summary
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Medicines
100.0
%
| 47 | 100.0 % | 43 | 100.0 % | -8.31% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Palestine
100.0
%
| 47 | 100.0 % | 43 | 100.0 % | -8.31% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Talal Nasereddin
CEO | Chief Executive Officer | 74 | 01/84/01 |
Director of Finance/CFO | - | 15/84/15 | |
Chief Tech/Sci/R&D Officer | - | 01/97/01 | |
Chief Tech/Sci/R&D Officer | 71 | 03/77/03 | |
Chief Administrative Officer | 54 | 01/92/01 | |
Comptroller/Controller/Auditor | - | 09/98/09 | |
Human Resources Officer | - | 06/09/06 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | - | 01/21/01 | |
Chief Administrative Officer | 54 | 01/92/01 | |
Talal Nasereddin
CEO | Chief Executive Officer | 74 | 01/84/01 |
Director/Board Member | - | 30/84/30 | |
Director/Board Member | - | 30/90/30 | |
Director/Board Member | - | 28/92/28 | |
Director/Board Member | - | 18/11/18 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 38,764,898 | 28,654,287 ( 73.92 %) | 0 | 73.92 % |
Company contact information
Sector
1st Jan change | Capi. | |
---|---|---|
-6.64% | 158M | |
+19.62% | 43.27B | |
+24.52% | 22.92B | |
+20.29% | 15.43B | |
+7.48% | 12.95B | |
+42.51% | 11.83B | |
-8.84% | 6.91B | |
-0.05% | 6.79B | |
-8.87% | 5.73B | |
+13.13% | 5.55B |
- Stock Market
- Equities
- BPC Stock
- Company Birzeit Pharmaceuticals Company